Reuters logo
8 个月前
BRIEF-FDA accepts the Biologics' license application for Avelumab for priority review
2016年11月29日 / 下午1点27分 / 8 个月前

BRIEF-FDA accepts the Biologics' license application for Avelumab for priority review

1 分钟阅读

Nov 29 (Reuters) - Pfizer Inc

* FDA accepts the biologics license application for Avelumab for the treatment of metastatic merkel cell carcinoma for priority review

* Pfizer announced fda has accepted for priority review EMD Serono's Biologics license application for Avelumab Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below